The Philadelphia judge in charge of mass tort cases said that she needs to balance the fact that Pennsylvania gives high deference to the choice of forum made by plaintiffs with whatever problems can be caused by that deference.
The issue of what forums plaintiffs and their lawyers select to bring mass torts in pharmaceutical and asbestos litigation has gotten a lot of attention recently. For example, the state Supreme Court recently rejected the request of pharmaceutical manufacturer Bayer to exercise its jurisdiction over whether Pennsylvania is the most convenient forum for several drug products liability cases brought by out-of-state plaintiffs in Philadelphia Common Pleas Court. And last month, drugmaker Pfizer asked that almost 50 cases that have been removed to the U.S. District Court for the Eastern District of Pennsylvania be consolidated into one multidistrict litigation.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
